Serial #87668721
LIVE

Serial Number

87668721

Owner

Aptorum Group Limited

Attorney

Sam Yip

Filing Date

Nov 1, 2017

Add to watchlist:

No watchlists yet
View on USPTO

Serial #87668721 Trademark

Serial Number: 87668721 • Registration: 6208265

Serial #87668721 is a trademark filed by Aptorum Group Limited on November 1, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Aptorum Group Limited (7 trademarks)

Unit 232, 2/F, Building 12W, Phase Three
Hong Kong , HK

Entity Type: 99

Trademark Details

Filing Date

November 1, 2017

Registration Date

December 1, 2020

Published for Opposition

September 15, 2020

Goods & Services

Pre-clinical and clinical services for pharmaceutical and diagnostic test formulation research, namely, pharmacological studies, toxicokinetic and pharmacokinetic studies, toxicity tests, bioequivalence studies, stability tests, clinical trials, clinical research, medical research in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; conducting clinical trials for diagnostic tests and for pharmaceutical preparations in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; scientific and toxicology research services in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; biopharmaceutical research for development of targeted therapies for use in the treatment of gastrointestinal diseases and disorders, diseases and disorders relating to woman's health, orthopedics and orthopedic injuries and conditions, and ophthalmological diseases, conditions and disorders; providing medical testing services for research purposes and medical and scientific research information in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; pre-clinical and clinical services for formulation research, namely, pharmacological studies, toxicokinetic and pharmacokinetic studies, toxicity tests, bioequivalence studies, stability tests, clinical trials, clinical research, medical research in the field of neurodegenerative diseases; conducting clinical trials for diagnostic tests and for pharmaceutical preparations in the field of neurodegenerative diseases; scientific and toxicology research services in the field of neuroscience and neurodegenerative diseases; biopharmaceutical research for development of targeted therapies for use in the treatment of neurodegenerative diseases and disorders; providing medical testing services for research purposes and medical and scientific research information in the fields of degenerative and neurodegenerative diseases; consulting for pharmacology and medical toxicology in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; consulting for pharmacology and toxicology in the field of neurodegenerative diseases and disorders

Surgical apparatus and instruments for use in the field of gastro-intestinal medicine, orthopedics and ophthalmology; Medical apparatus and instruments, namely, surgical robotic apparatus and non-invasive detection tools in the nature of medical imaging devices for detecting brain plaques; medical and surgical apparatus, instruments and parts therefor for use in magnetic resonance imaging and other imaging-guided surgery, including markers for use in patient registration in the nature of procedures used in computer assisted surgeries and tracking the location of instruments within the patient's body during image guided surgeries; medical and surgical apparatus, instruments and parts therefor for use in minimum invasive surgery; medical apparatus for the treatment of neurodegenerative diseases; medical instruments and articles, namely, analytical apparatus for diagnosis of neurodegenerative diseases; analysis apparatus for medical purposes, namely, non-invasive detection apparatus probes and imaging devices for use in the fields of neurology and neurobiology; diagnostic apparatus for medical purposes, for diagnosing plagues and images in brain for use in the fields of neurology and neurobiology; medical diagnostic apparatus for the detection of neurodegenerative diseases and conditions; surgical, medical apparatus and instruments for the prevention, treatment and repair of neurodegenerative diseases and disorders; medical testing apparatus used for the treatment of cognitive deficiencies, neurodegenerative diseases and for the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities

Pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of gastro-intestinal diseases and disorders; pharmaceutical preparations for the diagnosis, prevention and treatment of diseases and disorders relating to women's health, namely, gynecological diseases and disorders, endometrial disease and disorders; pharmaceutical products and preparations and traditional Chinese medicine for the treatment of orthopedic injuries and conditions; pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of ophthalmological diseases, conditions and disorders; pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of neurological diseases and disorders; pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations and traditional Chinese medicine for the diagnosis, prevention and treatment of cognitive deficiencies and neurodegenerative diseases and for the treatment of brain and spinal cord diseases or degenerative disorders and for improving neurological abilities

Providing targeted, individualized treatment regimens, therapies or combination therapy for patients suffering from gastro-intestinal diseases and disorders, diseases and disorders relating to woman's health, orthopedics and orthopedic injuries and conditions, and ophthalmological diseases, conditions and disorders; medical testing for diagnostic or treatment purposes in the fields of gastro-intestinal medicine, women's health, orthopedics and ophthalmology; providing targeted, individualized treatment regimens, therapies or combination therapy for patients suffering from neurodegenerative diseases and disorders; medical testing for diagnostic or treatment purposes in the field of neurodegenerative diseases and disorders

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 1, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Dec 1, 2020 R.PR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 6, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 6, 2020 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Oct 6, 2020 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 6, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 6, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 6, 2020 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 15, 2020 NPUB
PUBLISHED FOR OPPOSITION
Sep 15, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2020 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 7, 2020 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 30, 2020 CNSA
CASE RETURNED TO EXAMINATION
Jul 23, 2020 OTHE
NOTICE OF ALLOWANCE CANCELLED
Jul 23, 2020 IUCN
SOU EXTENSION 1 GRANTED
Jul 23, 2020 EX1G
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2020 CRFA
SOU EXTENSION 1 FILED
Jun 10, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 10, 2020 EEXT
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 9, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 7, 2020 GNRN
NON-FINAL ACTION E-MAILED
May 7, 2020 GNRT
NON-FINAL ACTION WRITTEN
May 7, 2020 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 28, 2020 ZZZX
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Apr 10, 2020 ATRQ
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Apr 10, 2020 PCBG
ASSIGNED TO PETITION STAFF
Apr 10, 2020 APET
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Mar 10, 2020 AITU
44(e) PETITION - RECEIVED
Feb 6, 2020 44EP
TEAS POST PUBLICATION AMENDMENT RECEIVED
Feb 6, 2020 EPPA
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 10, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 15, 2019 NPUB
PUBLISHED FOR OPPOSITION
Oct 15, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 25, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 6, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 6, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 6, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 6, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 6, 2019 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Aug 26, 2019 GPRN
PRIORITY ACTION E-MAILED
Aug 26, 2019 GPRA
PRIORITY ACTION WRITTEN
Aug 26, 2019 CPRA
NOTICE OF REVIVAL - E-MAILED
Aug 2, 2019 NREV
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 2, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 2, 2019 CRFA
ASSIGNED TO LIE
Aug 2, 2019 ALIE
PETITION GRANTED - RESPONSE RECEIVED
Aug 2, 2019 PGRR
ASSIGNED TO PETITION STAFF
Jul 30, 2019 APET
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 8, 2019 TROA
TEAS PETITION TO REVIVE RECEIVED
Jun 8, 2019 PROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Dec 7, 2018 GNRN
NON-FINAL ACTION E-MAILED
Dec 7, 2018 GNRT
NON-FINAL ACTION WRITTEN
Dec 7, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 13, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 12, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Nov 12, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 5, 2018 GNFN
FINAL REFUSAL E-MAILED
Sep 5, 2018 GNFR
FINAL REFUSAL WRITTEN
Sep 5, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 15, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 14, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 14, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
Feb 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
Feb 14, 2018 CNRT
ASSIGNED TO EXAMINER
Feb 12, 2018 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 14, 2017 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 11, 2017 NWOS
NEW APPLICATION ENTERED
Nov 4, 2017 NWAP